Stockscreener 앱 받기
6.797
6.39%
0.397
전일 마감가:
$6.40
열려 있는:
$5.62
하루 거래량:
33.80M
Relative Volume:
5.20
시가총액:
$81.71M
수익:
$1.38M
순이익/손실:
$-179.05M
주가수익비율:
-1.107
EPS:
-6.14
순현금흐름:
$-155.03M
1주 성능:
+129.26%
1개월 성능:
+245.63%
6개월 성능:
+142.31%
1년 성능:
+935.57%
1일 변동 폭
$4.80
$8.08
1주일 범위
$2.98
$8.08
52주 변동 폭
$0.16
$8.08
바이오엑셀 테라퓨틱스 Stock (BTAI) Company Profile
명칭
Bioxcel Therapeutics Inc
전화
203-643-8060
주소
555 LONG WHARF DRIVE, NEW HAVEN, CT
BTAI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
6.761 | 24.47M | 1.38M | -179.05M | -155.03M | -6.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
386.63 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.56 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.80 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.96 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
287.56 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
바이오엑셀 테라퓨틱스 Stock (BTAI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-02-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-08-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2023-07-17 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-03-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-01 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-04-06 | 재확인 | BofA Securities | Buy |
| 2021-11-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-04-09 | 개시 | Berenberg | Buy |
| 2021-02-01 | 개시 | UBS | Buy |
| 2020-10-30 | 개시 | Goldman | Buy |
| 2020-09-02 | 개시 | Jefferies | Buy |
| 2020-08-17 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-04 | 개시 | Guggenheim | Buy |
| 2020-04-01 | 개시 | BofA/Merrill | Buy |
| 2020-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-12 | 개시 | SunTrust | Buy |
모두보기
바이오엑셀 테라퓨틱스 주식(BTAI)의 최신 뉴스
BioXcel at Canaccord Genuity: Strategic Insights on Phase 3 Trials By Investing.com - Investing.com Canada
BioXcel Therapeutics (BTAI) Stock Is Extremely Volatile Today: What's Going On? - inkl
BioXcel Therapeutics Stock Soars Amid Positive Clinical and Patent Developments - StocksToTrade
BioXcel Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
BioXcel Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
BioXcel Therapeutics, Inc. SEC 10-Q Report - TradingView
Bioxcel Therapeutics Plunges 12.03% on Q2 Loss, Revenue Drop - AInvest
BioXcel Therapeutics Inc Reports Q2 2025 Earnings: EPS of -$1.56, Revenue Misses Estimates at $120K - GuruFocus
BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates - TradingView
BioXcel Therapeutics' Q2 2025 Earnings Disappointment: A Test of Biotech Resilience - AInvest
BioXcel's Breakthrough Agitation Drug Targets 23M Episodes Annually: Phase 3 Data Due This Month - Stock Titan
Bioxcel Therapeutics Surges 58.42% on $230M Volume Ranks 452nd in Market Activity as BXCL501 Trial Progress Fuels Investor Optimism - AInvest
BioXcel Therapeutics to Participate in Canaccord Genuity Growth Conference - AInvest
BioXcel Therapeutics Raises $30.4M, Meets Financing Covenant - TipRanks
Bioxcel Therapeutics (BTAI.O) Surges Over 21%: A Deep Dive Into the Drivers Behind the Unusual Move - AInvest
BioXcel’s BXCL501 Study: A Potential Game-Changer for Psychomotor Agitation Treatment - TipRanks
BioXcel Highlights BXCL501’s Market Potential for Agitation - TipRanks
BioXcel Therapeutics CEO to speak at Canaccord Genuity Growth Conference. - AInvest
BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
BioXcel CEO Reveals Next-Gen AI Neuroscience Innovations at Major Growth ConferenceStrategic Updates Coming - Stock Titan
Bioxcel Therapeutics (BTAI.O) Surges 12.6% Without Fundamental Catalyst: A Technical and Order-Flow Deep Dive - AInvest
Bioxcel Therapeutics (BTAI) Surges 28% on Intraday Rally: What’s Fueling the Momentum? - AInvest
BTAI Surges 27% on Unprecedented Momentum: What’s Fueling the Biotech Breakout? - AInvest
Top Penny Stocks to Watch: Ainos, SG Blocks, and BioXcel Therapeutics - AInvest
BioXcel Therapeutics Sees Stock Surge Amid Positive Phase 3 Results in At-Home Trial - timothysykes.com
Best Penny Stocks To ConsiderAugust 5th - MarketBeat
BioXcel Therapeutics Stock (BTAI) Opinions on Phase 3 SERENITY Trial Completion - Quiver Quantitative
BioXcel Therapeutics Anticipates Major Breakthrough with Completion of SERENITY At-Home Trial - StocksToTrade
Bioxcel Therapeutics (BTAI.O) Surges 17.17%—What’s Driving the Intraday Move? - AInvest
Bioxcel Therapeutics shares rise 4.38% premarket after publication in Frontiers in Pharmacology. - AInvest
Bioxcel Therapeutics Soars 11.11% on Positive Drug Study - AInvest
BioXcel Study Highlights Dexmedetomidine’s Potential Benefits - TipRanks
Bioxcel Therapeutics shares rise 11.78% premarket after positive study results for BXCL501 in chronic psychiatric disorders. - AInvest
BioXcel study shows dexmedetomidine reduces stress behaviors By Investing.com - Investing.com Nigeria
BioXcel study shows dexmedetomidine reduces stress behaviors - Investing.com India
BTAI files 424B5 to sell up to $3.5M in stock via ATM program - Stock Titan
BioXcel Therapeutics Announces Publication in Frontiers in - GlobeNewswire
Breakthrough Study: BioXcel's BXCL501 Could Transform Treatment of Chronic Psychiatric Disorders - Stock Titan
Mizuho Securities Maintains Hold Rating for Bioxcel Therapeutics with $2.00 Price Target - AInvest
Bioxcel Therapeutics Soars 27% Intraday: What's Fueling This Biotech Surge? - AInvest
BioXcel’s Clinical Breakthrough Marks Market Anticipation - timothysykes.com
Bioxcel Therapeutics (BTAI.O) Surges 13.39%: What’s Behind the Unusual Intraday Move? - AInvest
3 Penny Stocks to Watch: Tenon Medical, BioXcel Therapeutics, I-Mab - AInvest
Why Did Bioxcel Therapeutics Drop 6.69%? - AInvest
Bioxcel Therapeutics: Buy Rating Driven by SERENITY Trial Milestone and Strategic Expansion. - AInvest
BioXcel Therapeutics, Inc.Common Stock (Nasdaq:BTAI) Stock Quote - FinancialContent
Neuroendocrine Prostate Cancer Market Forecast Shows Accelerated CAGR Due to Diagnostic Advancements and Research Investment | DelveInsight - GlobeNewswire Inc.
H.C. Wainwright reiterates Buy rating on BioXcel Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Buy rating on BioXcel Therapeutics stock - Investing.com
Bioxcel Therapeutics (BTAI) Surges 29.9% on Phase 3 Trial Completion — What’s Next for the Biotech Breakout? - AInvest
BioXcel Therapeutics Stock Unveiled: Rollercoaster Insights - StocksToTrade
바이오엑셀 테라퓨틱스 (BTAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오엑셀 테라퓨틱스 주식 (BTAI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mehta Vimal | CEO and President |
Dec 16 '24 |
Sale |
0.36 |
3,117 |
1,131 |
59,605 |
| Steinhart Richard I | Chief Financial Officer |
Dec 16 '24 |
Sale |
0.36 |
577 |
207 |
20,932 |
| Rodriguez Javier | See Remarks |
Dec 16 '24 |
Sale |
0.36 |
430 |
153 |
24,423 |
| Yocca Frank | Chief Scientific Officer |
Dec 16 '24 |
Sale |
0.35 |
430 |
152 |
28,931 |
0.77%
2.87%
자본화:
|
볼륨(24시간):